France-based Valerio Therapeutics has announced the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches.
InVimmune aims to extend the reach of Valerio’s technology platforms into in vivo cell therapy through a novel immune reprogramming approach. The new company will leverage Valerio’s proprietary single-domain antibody platform together with targeted-delivery capabilities to develop programs across multiple therapeutic areas, with an initial focus on oncology.
Back in February 2025, Valerio revealed a strategic decision to discontinue all clinical trials due to “financing challenges,” choosing instead to focus resources exclusively on early-stage drug development.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!